Dexamethasone Sodium Phosphate

Verify with FDA CVM →

736 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
736
Total Reports
220
Deaths Reported
2990.0%
Death Rate

Active Ingredients

Dexamethasone Sodium Phosphate

Administration Routes

UnknownIntravenousSubcutaneousParenteralIntramuscularAuricular (Otic)OtherOralTopical

Species Affected

Dog 567
Cat 143
Unknown 23
Ferret 2
Horse 1

Most Affected Breeds

Domestic Shorthair 92
Retriever - Labrador 48
Terrier - Bull - American Pit 31
Shih Tzu 28
Unknown 27
Retriever - Golden 24
Chihuahua 23
Bulldog - French 20
Boxer (German Boxer) 18
Terrier (unspecified) 18

Most Reported Reactions

Vomiting 212
Lethargy (see also Central nervous system depression in 'Neurological') 149
Anaphylaxis 120
Death by euthanasia 114
Death 105
Other abnormal test result NOS 98
Diarrhoea 94
Pale mucous membrane 85
Not eating 79
Lethargy (see also Central nervous system depression in Neurological) 78
Anorexia 77
Fever 76

Outcome Breakdown

Ongoing
279 (39.1%)
Recovered/Normal
122 (17.1%)
Euthanized
112 (15.7%)
Died
109 (15.3%)
Outcome Unknown
86 (12.0%)
Recovered with Sequela
6 (0.8%)

Data Summary

Metric Value
Total adverse event reports 736
Reports involving death 220
Case-fatality rate (reported events) 2990.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dexamethasone Sodium Phosphate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 736 adverse event reports referencing Dexamethasone Sodium Phosphate, including 220 reports in which the animal died — a 2990.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Dexamethasone Sodium Phosphate. Reported administration routes include Unknown, Intravenous, Subcutaneous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dexamethasone Sodium Phosphate reports are Dog (567 reports), Cat (143 reports), Unknown (23 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (92), Retriever - Labrador (48), Terrier - Bull - American Pit (31) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dexamethasone Sodium Phosphate are Vomiting (212), Lethargy (see also Central nervous system depression in 'Neurological') (149), Anaphylaxis (120), Death by euthanasia (114). Of the 714 reports with a coded outcome, Ongoing is the leading category at 39.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dexamethasone Sodium Phosphate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial